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Abstract 
Recent case-controlled clinical studies show that bronchioalveolar carcinomas (BACs) are 
correlated with smoking. Nicotine, the addictive component of cigarettes, accelerates cell 
proliferation through nicotinic acetylcholine receptors (nAChRs). In this study, we show that 
human BACs produce acetylcholine (ACh) and contain several cholinergic factors including 
acetylcholinesterase (AChE), choline acetyltransferase (ChAT), choline transporter 1 (CHT1, 
SLC5A7), vesicular acetylcholine transporter (VAChT, SLC18A3) and nACh receptors (AChRs, 
CHRNAs). Nicotine increased the production of ACh in human BACs and ACh acts as a growth 
factor for these cells. Nicotine-induced ACh production was mediated by α7-, α3β2-, and β3-
nAChRs, ChAT and VAChT pathways. We observed that nicotine upregulated ChAT and 
VAChT. Therefore, we conjectured that VAChT antagonists, such as vesamicol, may suppress 
the growth of human BACs. Vesamicol induced potent apoptosis of human BACs 
in cell culture and nude mice models. Vesamicol did not have any effect on EGF or IGF-II-
induced growth of human BAC's. siRNA-mediated attenuation of VAChT reversed the apoptotic 
activity of vesamicol. We also observed that vesamicol inhibited Akt phosphorylation during cell 
death, and overexpression of constitutively active Akt reversed the apoptotic activity of 
vesamicol. Taken together, our results suggested that disruption of nicotine-induced cholinergic 
signaling by agents such as vesamicol may have applications in BAC therapy. 
 
KEY WORDS: Bronchioalveolar carcinoma, Acetylcholine, α7/3 nAChR, VAChT, CHT1, 
Vesamicol, Akt 
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Précis 
Findings that cholinergic signaling are critical to the survival of bronchioalveolar carcinoma cells 
should prompt immediate clinical testing of approved drugs that disrupt this pathway to 
determine if they can improve the efficacy of treatments for this form of lung cancer.
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Introduction 
Bronchioalveolar carcinoma (BAC) is a subtype of lung adenocarcinoma arising from type II 
pneumonocytes in the lung. The World Health Organization (WHO) revised its classification of 
BAC’s in 2004 to include lung adenocarcinomas, which grow in a lepidic fashion along the 
alveolar septa without invasion into the stroma, pleura, blood vessels or lymphatics (1-3). The 
incidence of pure BAC is about 4%; however, mixed subtypes, including BACs with stromal 
invasion and pulmonary adenocarcinoma with BAC-like morphological features, account for 
almost 20% of all non-small cell lung cancers (NSCLC) (4). Cigarette smoking is the leading risk 
factor for the development of lung cancer. It is estimated that smoking is associated with 80-
90% of lung cancer cases throughout the world (5).  Smoking has a stronger association with 
small cell lung cancer (SCLC) than with adenocarcinoma (6). BAC is a relatively rare type of 
adenocarcinoma; therefore, only a few epidemiological studies have investigated the 
relationship between BAC and smoking (7-9). 
Traditionally, the role of tobacco smoking in the etiology of human BAC originates from a 
series of early studies involving human lung cancer patients, most of which were non-smokers 
(1). These non-smoking lung cancer patients had higher incidence of BAC than other types of 
lung cancer. The resulting impression was that smoking is unimportant in the etiology of human 
BAC (1). However, these reports did not contain any cohort or case control studies that formally 
determined the relationship of human BACs to cigarette smoking.  
Epidemiological data have demonstrated an association between human BACs and 
smoking (7, 8, 10). The risk of developing BACs is greater for people who started smoking at a 
younger age, smoked for a longer time or smoked more cigarettes per day. Conversely, the risk 
decreases in proportion to the duration of smoking cessation. Smoking habits have been 
correlated to both the mucinous and non-mucinous form of human BACs (11). Rolen et al., 
(2003) performed a case-control study and compared smoking status of 198 BAC patients to an 
equal number of controls. They observed that the risk of BAC is strongly related to the smoking 
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history of patients.  They also found that both current and former smokers were at risk of 
developing BAC (9).  Recently, Boffeta et al., (2011) analyzed seven case controlled studies in 
the USA comprising of 799 cases of BACs and 15,859 controls. They found that ever smokers 
are at a two-fold greater risk of developing lung BAC as compared to never smokers. They also 
observed a positive correlation between the duration and amount of smoking and the 
development of lung BAC (8).   
Although cigarette smoke is comprised of a mixture of many compounds, nicotine is the 
addictive component of cigarette smoke (12). Several convergent studies have shown that 
nicotine promotes the progression of human BACs and confers resistance against 
chemotherapy (12, 13). All of these observations suggest that nicotine-induced mitogenic and 
pro-survival pathways contribute to the pathophysiology of BACs.  
The proliferative activity of nicotine is mediated by nicotinic acetylcholine receptors 
(nAChRs) (12). The endogenous ligand for nAChRs is acetylcholine (ACh) (14). Recent studies 
have shown that nAChRs are present in non-neuronal tissues, including lung cancer cells, lung 
epithelial cells, endothelial cells and keratinocytes (12). Small cell lung cancers (SCLCs) and 
squamous cell carcinoma of the lung (SCC-L) express all components of the ACh autocrine 
loop, including acetylcholinesterase (AChE), choline acetyltransferase (ChAT), vesicular 
acetylcholine transporter (VAChT), choline transporter1 (CHT1), nAChRs and muscarinic 
acetylcholine receptors. SCLC and SCC-L cells secrete ACh, which promotes their proliferation 
(14-17). Song et al., (2008) found that the muscarinic receptor antagonist Darifenacin displayed 
anti-tumor activity in human SCC-L in both cell culture and nude mice models (15, 18). Such 
observations suggest that the cholinergic network may be a viable molecular target in the 
therapy of human lung cancer.  
The present manuscript investigates whether the cholinergic loop exists in human BACs. 
We show that human BAC cell lines produce ACh and express cholinergic proteins. We also 
show for the first time that nicotine can amplify the components of the cholinergic loop in human 
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BACs. Nicotine increased the production of ACh in human BAC cell lines in a time- and dose-
dependent manner. ACh acted as a growth factor for human BAC cells. Nicotine upregulated 
VAChT and ChAT expression in human BAC cells. We conjectured that nicotine-induced 
increase of VAChT levels may provide a viable molecular target in human BACs. The VAChT 
antagonist vesamicol induced robust apoptosis of human BAC cells in both cell culture and in 
vivo models. Vesamicol did not affect EGF or IGF-II-induced growth pathways in human BACs. 
This finding suggests that the pro-apoptotic activity of vesamicol is specific to the acetylcholine-
signaling pathway in human BACs. The pro-apoptotic activity of vesamicol was mediated via 
suppression of Akt activation. The data presented in this paper characterizes the cholinergic 
system in human BACs and offers novel avenues for BAC therapy. The results of our 
experiments are relevant to BAC patients who are exposed to secondhand smoke or use 
nicotine-based cessation devices (e.g. patches and gums) to quit smoking.  
 
Methods 
Ethical use and care of laboratory animals.  
Nude mice (Charles River Laboratories International, Inc., Wilmington, MA, USA) were 
acclimatized for one week. They were housed in autoclaved cages with ad libitum access to 
food and water in HEPA-filtered racks and closely monitored by animal facility staff. All 
procedures involving nude mice were conducted according to the Animal Care and Use 
Guidelines in a facility accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) International and were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the Joan C. Edwards School of Medicine, Marshall 
University (Protocol # 421). 
 
 
 
7 
 
Authentication of Cell lines  
The human bronchioalveolar carcinoma (BAC) cell lines, A549, NCI-H358, and NCI-
H650 (hereinafter referred to as A549, H358 and H650), and the human SCC-L cell line H520 
were obtained from ATCC (Manassas, VA). The A549, H358 and H520 cells were authenticated 
by the ATCC Cell Authentication Service in October 2012. They used Short Tandem Repeat 
(STR) profiling for authentication of these cells, and the results are summarized in 
Supplementary Figure S1. The human BAC cell line H650 was passaged for less than six 
months and therefore did not require authentication. This cell line was obtained from ATCC 
which used STR profiling for its characterization. Primary human pulmonary alveolar epithelial 
cells (HPAEpiCs) were obtained from ScienCell (Carlsbad, CA).  These cells were characterized 
by ScienCell using immunostaining for specific markers. A certificate of analysis was provided. 
 
Cell Culture 
A549 and H358 were cultured in RPMI-1640, supplemented with 2.0 mM glutamine, 100 
units/mL penicillin, 50.0 µg/mL streptomycin, 1.0 mg/mL BSA, 1X insulin, transferrin, sodium 
selenite (ITS) supplement (Invitrogen Corp, Carlsbad, CA), 50 nM hydrocortisone and 1.0 µg/mL 
human EGF (15, 16). This medium will be referred to hereafter as serum-free RPMI (SF-RPMI). 
For a few experiments, the cells were rendered quiescent by incubating them in SF-RPMI 
containing ¼ ITS supplement, 12.5 nM hydrocortisone, 0.25 µg/mL EGF. This media, reduced 
serum-free RPMI, will be referred to hereafter as SF-RPMI-R. H650 was grown in a 1:1 mixture 
of DMEM and Ham’s F-12K, supplemented with 2.0 mM L-glutamine, 100 units/mL penicillin, 
50.0 µg/mL streptomycin, 0.02 mg/mL bovine insulin, 1X ITS, 50 nM hydrocortisone, 100 mM 
ethanolamine, 100 mM O-phosphorylethanolamine, 100 mM 3,3`,5-triiodo-L-thyronine, 5% (w/v) 
BSA, 0.5 mM sodium pyruvate, 10 mM HEPES, and 100 µg/mL EGF. The culture conditions for 
H520 and HPAEpiCs are described in Supplementary Methods. 
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Measurement of ACh production 
A549 cells were grown in SF-RPMI. On the day of the assay, 100 µM neostigmine (an 
acetylcholinesterase inhibitor) was added to each plate (16). Four hours after the addition of 
neostigmine, the indicated doses of nicotine were added and the cells were incubated at 37°C 
for 36 hours. The supernatant was collected and spun at 800g. Subsequently, the supernatant 
was lyophilized, reconstituted with 1/5 volume autoclaved water, and stored at -80°C until 
further analysis. The amount of ACh in the sample was measured using the 
Choline/acetylcholine Quantification Kit (Biovision, Milpitas, CA, USA) (15-17). Each sample 
was assayed in triplicate, and the whole experiment was performed two independent times for 
each cell line.  
 
Immunohistochemical staining of VAChT, ChAT in human BAC tissue microarray (TMA) 
and normal lung TMA 
Human BAC tissue microarray slides (Abnova, Walnut, CA, USA) were deparaffinized 
and rehydrated as described previously (19, 20). The immunostaining was performed using 
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturer’s 
protocol. The dilutions of primary antibodies used were 1:50 (polyclonal VAChT antibody) and 
1:25 (monoclonal ChAT antibody). The images were captured by phase contrast microscopy 
(Leica Microsystems, Wetzlar, Germany) at a magnification of 400X. The normal lung TMA (US 
Biomax Inc, Rockville, MD) was stained for VAChT and ChAT as described above. 
 
VAChT, ChAT and nAChR ELISA assays  
The concentration of VAChT and ChAT was measured using the VAChT ELISA Kit 
(Antibodies Online Inc., Atlanta, GA, USA) and the ChAT ELISA Kit (NovaTein Biosciences, 
Cambridge, MA), according to manufacturer’s instructions. The expression of nAChR subunits 
in human BAC cell lines was analyzed by using 7-, 3-, β2- and β3- nAChR ELISA Kits 
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(Antibodies Online Inc.). Each of these assays was completed in duplicate, and the whole 
experiment was performed two independent times for each cell line.  
 
TUNEL assays  
A549 or H358 cells (10,000 cells/well) were seeded into an 8-well chamber slide in SF-
RPMI and incubated overnight at 37°C (13, 19). Subsequently, the medium was replaced with 
SF-RPMI-R for 24 hours. After 24 hours, cells were treated with 100 nM nicotine in the presence 
or absence of 50 M vesamicol. Cells were incubated for 48 hours at 37°C. Apoptosis was 
measured by the colorimetric TUNEL Assay (Promega Corporation, Madison, WI, USA), 
according to manufacturer’s protocol. The magnitude of TUNEL-positive cells in the untreated 
control wells were considered to be equal to 1, and the TUNEL-positive cells in the remaining 
wells were calculated as fold-increase relative to the control. The experiment was performed 
two independent times with two replicates in each experiment. 
 
Caspase-3 activity assay  
Human BAC cells were incubated in SF-RPMI-R for 24 hours. Subsequently, cells were 
treated with 100 nM nicotine in the presence or absence of 50 M vesamicol for 48 hours at 
37°C. Lysates were made using the Caspase-3 Activity Kit (EMD Millipore Corporation, Billerica, 
MA, USA). Caspase-3 activity in untreated lysates was considered to be equal to 1, and the 
activity observed in treated lysates was calculated as fold-increase relative to the control cells. 
The experiment was performed two independent times with two replicates in each experiment. 
 
Antitumor studies in nude mice 
Four week-old male nude mice were acclimatized for one week and housed in 
autoclaved cages with ad libitum access to food and water in HEPA-filtered racks. A549 cells 
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were re-suspended in a 1:1 (v/v) solution of serum-free media and Matrigel matrix (BD 
Biosciences, San Jose, CA). One million cells were injected subcutaneously between the 
scapulae of each mouse (15, 21). After the tumors reached approximately 100 mm3, the mice 
were randomized into two groups, a control (N=8) and a treatment (N=8) group. The control 
group was fed an AIN-76A based diet containing 10% corn oil. The treatment group was fed a 
diet containing 50 mg vesamicol/kg food, (approximately 10 mg vesamicol/kg body weight) per 
day. Both groups were administered nicotine in their drinking water (200 g/mL in 2% saccharin 
sodium) (20, 21). The drug treatment was continued until tumors of the control group reached 
approximately 1500 mm3. Mice were weighed once per week. Their food consumption and 
water consumption was monitored daily. Tumor lengths (l), widths (w) and height (h) were 
measured daily (6 days a week) for each mouse. Tumor volumes were calculated as (l x w x 
h)/2 (22, 23). After euthanizing the mice, the tumors were excised. Half of the tumor was snap 
frozen in liquid nitrogen. Tumor lysates were prepared using T-Per lysis buffer (Pierce 
Biotechnology, Rockford, IL), according to manufacturer’s protocol (24). The other half of the 
tumor was fixed in 10% formalin buffered saline and used for immunohistochemistry.  
 
Statistical analysis 
All data was plotted using GraphPad Prism 5 Software, Inc (La Jolla, CA, USA), and was 
represented as the mean ± standard error of the mean (SEM). Results from the control and 
treated samples were compared using an analysis of variance followed by a Neumann-Keuls 
multiple comparison test. All analyses were completed using a 95% confidence interval. Data 
was considered significant when p < 0.05. 
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Results 
Cholinergic proteins are expressed on bronchioalveolar carcinomas.  
The cholinergic pathway proteins have been traditionally found in neuromuscular 
junctions and in neuronal cells (14). However, studies have shown that genes for these proteins 
are found in SCC-L and SCLC cells (14). ELISA experiments were performed to examine 
whether cholinergic proteins were expressed in human BAC cell lines and in HPAEpiCs. Figure 
1A shows that multiple nAChR subunits are expressed on A549, H358 and H650 human BAC 
cells. Similarly, HPAEpiCs also expressed a diverse array of nAChR subunits. Immunoblotting 
experiments were performed to examine the presence of AChE, ChAT, CHT1 and VAChT 
(Figure 1B) in human BAC cell lines and in HPAEpiCs. H520 human SCC-L cells were used as 
the positive control for both of the experiments. We observed that human BAC cell lines, as well 
HPAEpiCs normal lung cells, express VAChT, ChAT, AChE and CHT1.  The antibodies to 
VAChT, ChAT, CHT1 and AChE were found to be specific and showed only a single band at the 
correct molecular weight in full screen western blots (Supplementary Figure S2A-D). The 
expression of ChAT and VAChT was examined in human BAC tumors isolated from patients 
using BAC tissue microarray (TMA). The specific VAChT and ChAT antibodies described above 
were used for the immunostaining. Each TMA contained eighty-one samples of human BAC 
tumors from patients. Human BAC tumors displayed robust expression of both ChAT (Figure 
1C; left panel) and VAChT (Figure 1D; right panel). Both VAChT and ChAT were found to be 
expressed in the cytoplasm.  This observation is in agreement with previous data from several 
research groups showing that VAChT and ChAT are localized in the cytoplasm of cells (25-28).  
We also analyzed the expression of VAChT and ChAT in normal lung tissues using normal lung 
TMA (Supplementary Figure S3A-B).   This TMA contained 20 samples of normal lung tissue. 
We found that normal lung tissues also express VAChT and ChAT, and these proteins are 
localized in the cytoplasm.  
 
12 
 
Nicotine induces acetylcholine production in bronchioalveolar carcinomas.  
Next we wanted to assess the effect of nicotine on acetylcholine production in human 
BACs. We observed that nicotine increased ACh production from A549 cells in a concentration-
dependent manner (Figure 2A). The maximum ACh production (2 M) was observed at 100 nM 
nicotine and remained constant thereafter. A similar pattern was observed in H358 and H650 
human BAC cells (Figure 2A). We also performed a time-kinetics experiment with nicotine on 
A549 cells and found that the maximal ACh production (2 M) occurred at 36 hours and 
remained relatively constant thereafter (Figure 2B). Therefore, we selected a concentration of 
100 nM nicotine and a 36 hour time point for all of our ACh production experiments. A point to 
note here is that 100 nM nicotine is within the concentration range found in the plasma of an 
average smoker (1 nM - 1 M) (29).  
Studies by Song et al., (2003) have demonstrated that ACh acts as an autocrine growth 
factor for SCLC cells (16, 17). We analyzed the mitogenic activity of ACh in human A549 BAC 
cells and found that ACh stimulated the proliferation of A549 cells in a concentration-dependent 
manner; the maximal proliferation observed at 2 M ACh (Figure 2C: white bars). This finding is 
significant because the maximal mitogenic activity of ACh is similar to the amount of ACh 
secreted by human BACs. We repeated the BrdU cell proliferation assays in H358 human BAC 
cells and obtained similar results (Figure 2C: black bars). Our observations raise the possibility 
that nicotine induces the production of ACh in human BACs, which in turn, promotes the growth 
of human BACs in an autocrine manner. 
Next, we wanted to determine the role of nAChRs in nicotine-induced ACh production. 
The treatment of A549 cells with the generalized nAChR antagonist mecamylamine (MCA) 
suppressed nicotinic-induced ACh production, whereas atropine, an antagonist to the closely 
related muscarinic receptor, had little to no effect on nicotine-induced ACh levels. We obtained 
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similar results in another human BAC cell line H358. Our results show that nicotine promotes 
ACh levels in human BACs in an nAChR dependent manner (Supplementary Figure S4A).  
The next series of experiments aimed to investigate which specific nAChR subunits were 
responsible for nicotine-induced ACh production. Our data showed that the treatment of A549 
and H358 human BAC cells with 7-nAChR subunit antagonists, methyllycaconitine (MLA) and 
-bungarotoxin (-BT), ablated nicotine-induced ACh production. Additionally, 1 μM of -
conotoxin MII (-CT; 3β2 and β3 subunit antagonist) reversed the pro-secretory effect of 
nicotine, whereas DHβE (3β2 and 4β2 nAChR antagonist) had little to no effect 
(Supplementary Figure S4B). Taken together, these results suggest that nicotine-induced ACh 
secretion is mediated via nAChRs, specifically through the 7-, 3β2- and β3-containing-nAChR 
subunits.  
Finally, we wanted to examine the effect of choline/acetylcholine transporters on 
nicotine-induced ACh production. The treatment of A549 and H358 cells with hemicholinium (an 
antagonist of CHT1) suppressed nicotine-induced ACh secretion. Similarly, vesamicol (an 
antagonist of VAChT) potently abrogated nicotine-induced ACh production (Supplementary 
Figure S4C). Taken together, this shows that CHT1 and VAChT function are vital for nicotine-
induced ACh production. 
 
Nicotine increases VAChT and ChAT levels in human BAC cells.  
We wanted to investigate whether nicotine promoted ACh secretion via the 
VAChT/ChAT pathway in BAC cells. We used an ELISA kit to measure VAChT and ChAT 
levels, which allowed us to quantitate these levels in an accurate and sensitive manner. We 
observed that the VAChT ELISA kit detected VAChT levels in asynchronous A549, H358, H650 
BAC cells and HPAEpic normal lung cells (Supplementary Figure S5). The relative pattern of 
VAChT expression in the ELISA correlated well with the results obtained from western blotting 
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(Figure 1B; fourth panel). ELISA The treatment of A549 cells with 100 nM nicotine caused a 4-
fold increase in VAChT levels (Figure 3A) and a 1.5-fold increases in ChAT levels (Figure 3B). 
Similarly, nicotine increased VAChT levels in H358 by 5.5-fold and ChAT levels by 1.4-fold 
(Figure 3A and 3B). We also tested the effect of nicotine on AChE and CHT1 in human BACs. 
We found that nicotine decreased AChE levels in H358 and A549 human BACs (Figure 3C). 
The levels of CHT1 were relatively unaffected by nicotine in both the cell lines (Figure 3C). 
 
The VAChT antagonist vesamicol causes apoptosis in human BACs.  
Our results showed that nicotine-induced ACh production was blocked by the VAChT 
inhibitor vesamicol (Supplementary Figure S4C). It may be envisaged that vesamicol will 
suppress nicotine-induced ACh production and thereby block ACh-induced growth of human 
BACs. Additionally, we conjectured that nicotine-induced upregulation of VAChT should provide 
a viable molecular target for vesamicol therapy in human BACs. MTT assays (Supplementary 
Methods online) demonstrated that vesamicol decreased the viability of nicotine-treated A549 
and H358 human BAC lines in a concentration-dependent manner. The maximum reduction in 
cell viability was observed at 50 M vesamicol (Figure 4A). Therefore, we used 50 M 
vesamicol for all further experiments. 
 Next, we wanted to examine whether vesamicol induced apoptosis in human BAC cell 
lines. Quiescent A549 and H358 cells were treated with 100 nM nicotine in the presence or 
absence of 50 M vesamicol. Apoptosis was measured by TUNEL assays. Figure 4B shows 
that vesamicol caused robust apoptosis in both A549 and H358 human BACs. The results of the 
TUNEL assays were verified by caspase-3 activity assay. We observed that vesamicol caused 
2.5- to 3-fold increase in apoptosis relative to nicotine-treated human BAC cells (Figure 4C).  
 We also wanted to assess the effect of vesamicol on other mitogenic signaling pathways 
in human BACs (30-35). Several convergent studies indicate that EGF and IGF-II are potent 
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growth factors for human BAC cells (30-35).  We performed a BrdU assay (Supplementary 
Methods online) to test the effect of vesamicol on EGF-induced proliferation of human BAC cell 
lines. We found that vesamicol has no effect on EGF-induced proliferation of A549 and H358 
human BAC cell lines (Figure 4D).  Similarly, vesamicol did not affect IGF-II-induced 
proliferation of human A549 and H358 cells (Figure 4E). Our findings seem to suggest that 
vesamicol specifically inhibits the acetylcholine-proliferative pathway in human BACs. 
 
Vesamicol induces apoptosis in human BAC cells by specifically targeting VAChT 
Vesamicol is a well characterized antagonist of VAChT (36).  However, previous studies 
indicate that vesamicol also binds to the sigma-receptor in several types of human cancer cells 
(37, 38).  We wanted to examine whether vesamicol induced apoptosis in human BAC cells by 
specifically targeting VAChT. For this purpose, we used siRNA methodology to suppress the 
expression of VAChT or sigma receptor in A549 cells. A549 cells were transfected with VAChT-
siRNA or sigma-receptor-siRNA (Supplementary Methods Online). Eighteen hours post 
transfection, the cells were rendered quiescent by incubating them in SF-RPMI-R medium for 24 
hours (19). Subsequently, the cells were treated with 100nM nicotine in the presence or 
absence of 50 M vesamicol for 48 hours at 37°C. A549 cells transfected with a non-targeting 
control-siRNA was used as the negative control for the experiment. After 48 hours cell lysates 
were made and vesamicol-induced apoptosis was measured by the caspase-3 activity assay.   
We observed that vesamicol-induced apoptosis was decreased upon transfection of 
VAChT-siRNA and unaffected by sigma-receptor-siRNA. The apoptotic activity of vesamicol 
was also unaffected by the control non-targeting siRNA (Figure 5A). We repeated these 
experiments in H358 human BAC cells and obtained similar results (Figure 5B). These 
experiments were also repeated with a second independent VAChT-siRNA (Ambion Inc., Grand 
Island, NY) and similar results were obtained (Figure 5C and D).  
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Parallel transfection experiments were performed to test the efficacy of   VAChT-siRNA 
and sigma-receptor-siRNA in A549 cells. ELISA assays show that the levels of VAChT are 
robustly suppressed upon transfection with both sets of VAChT-siRNA (Supplementary Figure 
S6A and S6B) in A549 and H358 human BAC cells. Western blotting experiments show that the 
levels of sigma receptor are ablated upon transfection of sigma-receptor-siRNA (Supplementary 
Figure S6C and S6D) in both A549 and H358 cells.  
We also examined whether vesamicol was targeting the VAChT pathway at 
concentrations lower than 50µM.  We chose 10µM and 25µM vesamicol for our experiments.  
Caspase-3 activity assays show that the cellular apoptosis induced by 10µM vesamicol was 
suppressed by two independent sets of VAChT-siRNA in both A549 and H358 cells 
(Supplementary Figure S7A and S7B). Similarly, the transfection of VAChT-siRNA efficiently 
abrogated the apoptotic activity of 25µM vesamicol in nicotine-treated A549 and H358 cells 
(Supplementary Figure S7C and S7D).  ELISA assays indicate that both the VAChT-siRNA 
decreased the expression of VAChT in A549 and H358 cells (Supplementary Figure S7E). 
Taken together, our data show that vesamicol caused apoptosis in human BAC cells by 
specifically targeting the VAChT pathway.  
 
Vesamicol-induced apoptosis is mediated by the Akt pathway in human BACs. 
 The Akt signaling pathway plays a vital role in nAChR signaling in normal lung cells and 
lung cancer cells (12). We observed that the treatment of A549 and H358 human BAC cells with 
nicotine and vesamicol caused potent decreases in phosphorylated-Akt levels (Figure 6A and 
B). The levels of both phosphorylated-Akt (Thr308) and phosphorylated-Akt (Ser473) are 
robustly suppressed upon vesamicol treatment, whereas total Akt levels remain constant 
(Figure 6A and 6B, respectively). Western blotting analysis also showed that vesamicol had little 
to no effect on the expression of phosphorylated-Akt in untreated A549 (or H358) cells (Figure 
6C and 6D). The transfection of constitutively active Akt (pcDNA3-HA-Akt-CA; Supplementary 
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Methods Online) reversed the apoptotic effect of vesamicol, demonstrating that vesamicol 
induces cell death by suppressing Akt activation (Figure 6E and 6F). Western blotting analysis 
confirms the over expression of HA-tagged Akt in A549 and H358 human BAC lines upon 
transfection (Supplementary Fig. S8A and S8B). 
 
Vesamicol inhibited the growth of human A549 cells in vivo.  
The anti-tumor activity of vesamicol was examined in vivo using a nude mice model (15, 
21). A549 human BAC cells were injected between the scapulae of nude mice. The tumors were 
allowed to grow until approximately 100 mm3, after which they were randomized into two 
groups. The control group was administered nicotine in the drinking water. The “vesamicol 
group” was administered 50 mg vesamicol/kg food along with nicotine. Our results showed that 
the administration of vesamicol decreased the tumor growth rate of A549 human BAC tumors 
(Figure 7A). The administration of 50 mg vesamicol/kg food in the diet was well tolerated and 
caused no discomfort or weight loss in mice (mean control = 25.6 ± 0.6 g; mean vesamicol 
treated = 25.2 ± 0.5 g). Additionally, food intake (mean control = 6.2 ± 0.04 g/day; mean 
vesamicol-treated = 6.2 ± 0.04 g/day) and water consumption (mean control = 11.0 ± 0.4 
mL/day; mean vesamicol-treated = 11.2 ± 0.3 mL/day) was similar between groups. 
H and E staining of the tumors revealed the presence of apoptotic bodies in the tumors 
belonging to the vesamicol-treated mice (Figure 7B). Caspase-3 activity assays indicate that 
tumor lysates from vesamicol-treated mice displayed about 2.5-fold greater apoptosis relative to 
control nicotine-treated mice (Figure 7C). Our data from cell culture suggested that vesamicol 
induced apoptosis by suppression of Akt activation. We wanted to investigate whether 
vesamicol-treated tumors had lower levels of phosphorylated-Akt. Western blotting analysis 
revealed that vesamicol-treated tumors had substantially lower levels of phosphorylated-Akt 
(Thr308 and Ser 473) relative to nicotine-treated A549 tumors (Figure 7D; top two panels). The 
total Akt levels were similar in all four pairs of tumors (Figure 7D; third panel from the top). 
18 
 
Taken together, these data indicate that vesamicol decreases tumor growth rates of A549 
human BAC tumors in vivo by inducing robust apoptosis via an Akt-dependent pathway.  
 
Discussion 
Our study shows for the first time that human BACs produce ACh and contain a 
functional acetylcholine-signaling system. A functional cholinergic loop has also been detected 
in SCLCs, SCC-Ls and normal bronchial epithelial cells (14). Most importantly, nicotine 
regulates the cholinergic machinery and increases ACh levels by about 10-fold in human BACs. 
Nicotine upregulates the levels of cholinergic proteins, namely VAChT and ChAT, and 
concomitantly downregulates AChE in human BACs. Nicotine-induced increases of VAChT and 
ChAT promote ACh content and its transport into the extracellular environment. On the other 
hand, nicotine decreases AChE levels, which in turn suppress ACh degradation. Thus, the 
enhanced levels of ACh provide proliferative stimuli to human BACs. The amplification of the 
cholinergic network by nicotine offers novel therapeutic strategies for BAC therapy. These 
phenomena are highly significant since about 30% of lung cancer patients continue to smoke, 
use nicotine-based cessation patches or gum, or are exposed to environmental tobacco smoke 
after their diagnosis (39-41).  
 We observed that nicotine caused a 3-fold increase in VAChT and ChAT levels in 
human BAC cells. This led us to hypothesize that antagonists of VAChT should attenuate 
nicotine-induced ACh production and thereby suppress the growth of human BACs. As a “proof-
of-principle” we decided to use the well-characterized VAChT antagonist, vesamicol, for our 
experiments. Our hypothesis was supported by the results of Song et al., (2003) who showed 
that vesamicol suppressed the growth of H82 human SCLC cells in vitro. We believe that our 
results are the first to report characterizing the anti-cancer activity of VAChT antagonists in 
human BAC using both cell culture and in vivo model systems. We found that vesamicol 
induced robust apoptosis in human BAC cells in both cell culture and in vivo systems.  
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A survey of literature shows that only very few studies have evaluated the anti-tumor 
activity of vesamicol. Ogawa et al., (2009) evaluated radioiodinated vesamicol analogs for tumor 
imaging and anti-tumor activity (42, 43). They found that radioiodinated-vesamicol-analogs 
suppressed the growth of human prostate cancer cells in mice model. However, their results 
showed that vesamicol exerted its anti-tumor activity by binding to the sigma receptor on DU145 
prostate cancer cells (42). Several convergent studies have shown that vesamicol is also a 
ligand for the sigma-receptor. However, our experiments involving VAChT-siRNA and sigma-
receptor-siRNA showed that the anti-cancer activity of vesamicol was specifically mediated by 
VAChT. It is possible that sigma-receptors do not play a vital role in nicotine-induced 
proliferative signaling in human BAC cells. 
 The present manuscript shows that apoptotic effects of vesamicol are mediated via 
suppression of the Akt pathway. Clinical studies have shown that the activation of Akt is highly 
prevalent in human BAC tumors. Nicotine causes rapid activation of Akt and its downstream 
substrates. Studies by West et al., (2001) have speculated that inhibition of the Akt pathway 
may be a viable strategy for treatment of tobacco-related lung cancers (44, 45). The EGFR 
inhibitors Gefitinib and Erlotinib have been shown to suppress Akt phosphorylation in human 
lung cancer cells (46, 47). Similarly, PI-3kinase/Akt inhibitors, i.e. LY294002 and deregulin, 
suppress proliferation of human BAC cells in vitro and in mouse models of tobacco 
carcinogenesis (48). Our results suggest that VAChT-antagonists such as vesamicol are 
another class of therapeutic agents capable of inhibiting activated Akt in human BACs. 
The acetylcholine-signaling pathway has been found to regulate multiple cellular 
functions, such as proliferation, cell-to-cell contact, differentiation and cytoskeletal integrity (14). 
Apart from lung cancer cells, endothelial cells, mesothelial cells, immune cells and keratinocytes 
have been found to synthesize, transport and degrade acetylcholine (14). The pharmacological 
manipulation of this non-neuronal cholinergic system by agents, such as vesamicol, could lead 
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to the development of novel therapies for multiple tobacco-related diseases including lung 
cancer. 
 
Acknowledgements 
We thank Dr. Srikumar Chellappan and his laboratory for continuous support. We are grateful to 
Adam W. Buckley and Jarrod C. Harman for technical assistance. We also acknowledge Dr. 
Woodgett providing us the constructs used in this study. This work was supported by the grants 
Young Clinical Scientist Award (#82115) from the Flight Attendant Medical Association, Miami, 
FL and 1R15CA161491-01A1 from NIH to PDG. YCC is funded by NIH Grant 5P20RR016477 
and 8P20GM103434 (PI: Gary O. Rankin). AMD and KCB are recipients of graduate fellowships 
from the WVSGC. CMC is the recipient of a GIAR undergraduate research grant from the 
Sigma-Xi Society. We thank Luke Damron for editorial support and suggestions. 
 
 
21 
 
References 
1. Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML. Systemic approaches for 
multifocal bronchioloalveolar carcinoma: is there an appropriate target? Oncology 
(Williston Park). 2010;24:888-98, 900. 
2. Saintigny P, Wistuba, II, Kim ES. Bronchioloalveolar carcinoma: a translational 
perspective. Oncology (Williston Park). 2010;24:907-8, 14. 
3. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T.et al. 
Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC et al., 
editors. World health classification of tumours pathology and genetics of tumours of the 
lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004. p. 35-44. 
4. Ebbert JO, Chhatwani L, Aubry MC, Wampfler J, Stoddard S, Zhang F, et al. Clinical 
features of bronchioloalveolar carcinoma with new histologic and staging definitions. J 
Thorac Oncol. 2010;5:1213-20. 
5. The Health Consequences of Smoking. A report of the Surgeon General's Office on 
Smoking and Health, DHHS, Washington DC.  2004. 
6. Cancer IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.  
Tobacco Smoke and Involuntary Smoking: IARC, Lyon, France; 2004. p. 51-1187. 
7. Garfield D. Mucinous and nonmucinous bronchioloalveolar carcinoma and smoking. Am 
J Clin Pathol. 2010;133:341-2. 
8. Boffetta P, Jayaprakash V, Yang P, Asomaning K, Muscat JE, Schwartz AG, et al. 
Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled 
analysis of seven case-control studies in the International Lung Cancer Consortium 
(ILCCO). Cancer Causes Control. 2011;22:73-9. 
9. Rolen KA, Fulton JPT, D. J., Strauss GM. Bronchoalveolar carcinoma (BAC) of the lung 
is related to cigarette smoking: A case-control study from Rhode Island (RI).  2003 
ASCO Annual Meeting; 2003. 
22 
 
10. Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ. 
1992;304:541-3. 
11. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, et al. EGFR and 
K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and 
elaboration of a combined clinicopathologic and molecular scoring system to predict 
clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009;131:478-89. 
12. Singh S, Pillai S, Chellappan S. Nicotinic acetylcholine receptor signaling in tumor 
growth and metastasis. J Oncol. 2011;2011:456743. 
13. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits 
apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc 
Natl Acad Sci U S A. 2006;103:6332-7. 
14. Song P, Spindel ER. Basic and clinical aspects of non-neuronal acetylcholine: 
expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer 
therapy. J Pharmacol Sci. 2008;106:180-5. 
15. Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, et al. Activated cholinergic 
signaling provides a target in squamous cell lung carcinoma. Cancer Res. 
2008;68:4693-700. 
16. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, et al. Acetylcholine is 
synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. 
Cancer Res. 2003;63:214-21. 
17. Song P, Sekhon HS, Proskocil B, Blusztajn JK, Mark GP, Spindel ER. Synthesis of 
acetylcholine by lung cancer. Life Sci. 2003;72:2159-68. 
18. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, et al. M3 muscarinic 
receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated 
protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res. 
2007;67:3936-44. 
23 
 
19. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated 
regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer 
Inst. 2011;103:317-33. 
20. Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, et al. MG624, an alpha7-
nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis. 
2012;15:99-114. 
21. Brown KC, Witte TR, Hardman WE, Luo H, Chen YC, Carpenter AB, et al. Capsaicin 
displays anti-proliferative activity against human small cell lung cancer in cell culture and 
nude mice models via the E2F pathway. PLoS One. 2010;5:e10243. 
22. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic 
(nude) mice. Cancer Chemother Pharmacol. 1989;24:148-54. 
23. Shabbir M, Thompson CS, Mikhailidis D, Morgan RJ, Burnstock G. Extracellular ATP 
attenuates the growth of hormone refractory prostate cancer in vivo. Eur Urology 
Supplements. 2003;2:24-7. 
24. Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, et al. A small 
molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and 
growth of human tumor xenografts in nude mice. Cancer Res. 2008;68:3810-8. 
25. Schafer MK, Weihe E, Erickson JD, Eiden LE. Human and monkey cholinergic neurons 
visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular 
acetylcholine transporter. J Mol Neurosci. 1995;6:225-35. 
26. Tayebati SK, Tomassoni D, Di Stefano A, Sozio P, Cerasa LS, Amenta F. Effect of 
choline-containing phospholipids on brain cholinergic transporters in the rat. Journal of 
the neurological sciences. 2011;302:49-57. 
27. Papka RE, Traurig HH, Schemann M, Collins J, Copelin T, Wilson K. Cholinergic 
neurons of the pelvic autonomic ganglia and uterus of the female rat: distribution of 
axons and presence of muscarinic receptors. Cell Tissue Res. 1999;296:293-305. 
24 
 
28. Takahara Y, Maeda M, Nakatani T, Kiyama H. Transient suppression of the vesicular 
acetylcholine transporter in urinary bladder pathways following spinal cord injury. Brain 
Res. 2007;1137:20-8. 
29. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates 
angiogenesis and promotes tumor growth and atherosclerosis. Nature Medicine. 
2001;7:833-9. 
30. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ, 2nd. Functional selectivity of 
EGF family peptide growth factors: implications for cancer. Pharmacology & 
therapeutics. 2009;122:1-8. 
31. Siegfried JM. Detection of human lung epithelial cell growth factors produced by a lung 
carcinoma cell line: use in culture of primary solid lung tumors. Cancer Res. 
1987;47:2903-10. 
32. Domingo G, Perez CA, Velez M, Cudris J, Raez LE, Santos ES. EGF receptor in lung 
cancer: a successful story of targeted therapy. Expert Rev Anticancer Ther. 
2010;10:1577-87. 
33. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II 
induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene. 
2005;24:7310-9. 
34. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic 
insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer. 
2009;10:262-72. 
35. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung 
cancer. J Thorac Oncol. 2008;3:815-8. 
36. Bahr BA, Parsons SM. Acetylcholine transport and drug inhibition kinetics in Torpedo 
synaptic vesicles. J Neurochem. 1986;46:1214-8. 
25 
 
37. Wilke RA, Mehta RP, Lupardus PJ, Chen Y, Ruoho AE, Jackson MB. Sigma receptor 
photolabeling and sigma receptor-mediated modulation of potassium channels in tumor 
cells. J Biol Chem. 1999;274:18387-92. 
38. Efange SM, Mach RH, Smith CR, Khare AB, Foulon C, Akella SK, et al. Vesamicol 
analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol 
receptor. Biochem Pharmacol. 1995;49:791-7. 
39. Johnson BE. Tobacco and lung cancer. Prim Care. 1998;25:279-91. 
40. Johnson BE, Cortazar P, Chute JP. Second lung cancers in patients successfully treated 
for lung cancer. Semin Oncol. 1997;24:492-9. 
41. Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE, Jr., Ihde DC, et al. 
Smoking abstinence and small cell lung cancer survival. An association. Jama. 
1980;244:2175-9. 
42. Ogawa K, Shiba K, Akhter N, Yoshimoto M, Washiyama K, Kinuya S, et al. Evaluation of 
radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide 
receptor therapy. Cancer Sci. 2009;100:2188-92. 
43. Ogawa K, Kanbara H, Shiba K, Kitamura Y, Kozaka T, Kiwada T, et al. Development 
and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging 
agent. EJNMMI research. 2012;2:54. 
44. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt 
activation by nicotine and a tobacco carcinogen modulates the phenotype of normal 
human airway epithelial cells. J Clin Invest. 2003;111:81-90. 
45. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced 
cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt 
pathway in vitro and in vivo. Cancer Res. 2004;64:446-51. 
26 
 
46. Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S. Gefitinib inhibits MUC5AC 
synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer. 2005;50:19-
24. 
47. Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, et al. Roles of MKK1/2-
ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced 
Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol 
Cancer Res. 2009;7:1378-89. 
48. Denlinger CE, Rundall BK, Jones DR. Inhibition of phosphatidylinositol 3-kinase/Akt and 
histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and 
in vivo. J Thorac Cardiovasc Surg. 2005;130:1422-9. 
 
27 
 
 
 
Figure 1. Human BACs and normal human alveolar epithelial cells (HPAEpiCs) express 
cholinergic proteins. (A) ELISA assays show that human BAC cell lines and HPAEpiCs express 
multiple nAChR subunits. The assay was completed in duplicate, and the whole experiment was 
performed two independent times. Results indicated by a different letter are significantly 
different (P < 0.05). (B) HPAEpiCs and human BACs express AChE, ChAT, CHT1 and VAChT. 
H520 human SCC-L cells were used as the positive control for the experiments outlined in (A) 
and (B). GAPDH was used as the loading control, and the results were quantitated by 
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densitometric analysis. The experiment was repeated twice, and the representative data is 
shown. (C) and (D) Immunohistochemistry of the human BAC microarray showed that BAC 
tumors (isolated from patients) express ChAT and VAChT in the cytoplasm, adjacent to the 
hemotoxylin-counterstained dark nuclei in the tissue samples. A tumor microarray containing 81 
cores of human BACs was used for these experiments and four panels of representative photos 
are shown. Scale bar = 20 µm. 
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Figure 2. Nicotine induces the production of the growth factor ACh in human BACs. (A) Nicotine 
caused a concentration-dependent increase in ACh production in A549, H358 and H650 human 
BAC cell lines. (B) Time kinetics of nicotine-induced ACh production in A549 human BAC cells. 
The maximal ACh production was observed at 100 nM nicotine at 36 hours. (C) ACh stimulated 
proliferation of A549 and H358 cells. BrdU assays show that 2 µM of ACh (which is 
approximately the amount of ACh produced in nicotine-treated BAC cells) caused a 4- to 4.5-
fold increase in proliferation of A549 and H358 human BACs. Each sample was analyzed in 
triplicate. Data represent mean + SEM from two independent experiments. Results indicated by 
a different letter are significantly different (P < 0.05). 
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Figure 3. Effect of nicotine on cholinergic proteins in human BACs. (A) The treatment of A549 
and H358 cells with 100 nM nicotine caused 4- to 5-fold increase in VAChT levels. (B) Nicotine 
produces a modest increase in ChAT levels. (C) Nicotine decreases AChE levels in both A549 
and H358 cells. The levels of CHT1 are relatively unaffected by nicotine in human BAC cells. 
Data represent mean + SEM from two independent experiments. Each sample was analyzed in 
triplicate. Results indicated by a different letter are significantly different (P < 0.05). 
 
31 
 
 
32 
 
Figure 4. Vesamicol caused apoptosis in human BAC cells. (A) MTT assays showed that 
vesamicol decreases the viability of A549 and H358 cells in a concentration-dependent manner. 
Each sample was analyzed in triplicate. (B) The treatment of human BAC cell lines with 50 µM 
vesamicol caused 2.5- to 3-fold apoptosis in nicotine-treated A549 and H358 cells. (C) The 
apoptotic activity of vesamicol was confirmed with caspase-3 activity assay and similar results 
were obtained. (D) Vesamicol had no effect on EGF-induced proliferation of A549 and H358 
cells.  BrdU assays show that the treatment of A549 and H358 human BAC cells with 10 ng/ml 
EGF causes robust proliferation. The addition of 50 µM vesamicol along with EGF produced no 
effect on EGF-induced proliferation of human BACs.  (E) BrdU assays demonstrate that 
vesamicol does not suppress IGF-II-induced proliferation of human BAC cell lines.  Each 
sample was analyzed in duplicate.  Data represent mean + SEM from two independent 
experiments. Results indicated by a different letter are significantly different (P < 0.05). 
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Figure 5. Vesamicol-induced apoptosis is specifically mediated by VAChT in human BAC cells. 
(A) Caspase-3 activity assays showed that the transfection of VAChT-siRNA reversed 
vesamicol-induced apoptosis in nicotine-treated A549 cells, whereas transfection of sigma-
receptor-siRNA (SigmaR-siRNA) or control-siRNA has no effect. (B) The experiment was 
repeated in H358 human BAC cells, and similar results were obtained. (C) The suppression of 
VAChT, with another independent VAChT-siRNA (VAChT-siRNA-2), abrogated vesamicol-
induced apoptosis in A549 human BAC cells. (D) The experiment was repeated in H358 cells, 
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and similar results were obtained. Each sample was analyzed in duplicate. Data represent 
mean + SEM from two independent experiments. Results indicated by a different letter are 
significantly different (P < 0.05).  
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Figure 6. The apoptotic activity of vesamicol is mediated by the Akt pathway. (A) The treatment 
of A549 and H358 human BAC cells with nicotine and vesamicol inhibited Akt phosphorylation 
at Thr-308. (B) Vesamicol decreased the levels of phospho-Akt (Ser-473) in nicotine-treated 
A549 and H358 cells. (C) Vesamicol had no effect on the levels of phospho-Akt (Thr-308) in 
untreated A549 and H358 cells. (D) The treatment of quiescent A549 and H358 cells 50 µM 
vesamicol does not affect phospho-Akt (Ser-473) levels.  (E) The transfection of pcDNA3-HA-
Akt-CA (T308D, S473D) reverses the apoptotic activity of vesamicol, whereas transfection of 
the empty vector had no effect on vesamicol-induced apoptosis in A549 human BAC cells. (F) 
The transfection experiment was repeated in H358 cells and similar results were obtained. Data 
represent mean + SEM from two independent experiments. Each sample was analyzed in 
duplicate. Results indicated by a different letter are significantly different (P < 0.05). 
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Figure 7. Vesamicol induces apoptosis of human BAC tumors in vivo. (A) The administration of 
vesamicol (50 mg vesamicol/kg food) decreased the growth rate of A549 human BAC tumors 
xenografted in nude mice. The nude mice experiments comprised of eight mice per group. (B) 
The tumors from the mice were excised and stained with H & E. The black arrow shows the 
presence of apoptotic bodies in the tissue sections. The vesamicol-treated tumors (right panel) 
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showed a greater number of apoptotic bodies relative to the mice administered vehicle (left 
panel). Scale bar = 500 µm. (C) An aliquot of the tumors from nude mice were frozen and 
lysates were made. Caspase-3 activity of these lysates was measured. The vesamicol-treated 
tumors had higher caspase-3 activity (indicating higher apoptosis) than the tumors in the control 
group. (D) Western blotting analysis showed that vesamicol-treated tumors showed lower levels 
of phospho-Akt (Thr308) and phospho-Akt (Ser473). The western blot was quantitated using 
NIH ImageJ 1.46p. Data represent mean + SEM. Results indicated by a different letter or an 
asterisk are significantly different (P < 0.05). 
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Supplementary Methods 
Reagents, Antibodies and Constructs 
Nicotine, α-bungarotoxin (α-BT, α7-nAChR antagonist), dihydro-β-erythroidine 
hydrobromide (DHβE, α4β4- and α4β2-nAChR antagonist), hemicholinium (ChAT 
antagonist) and EGF were purchased from Sigma-Aldrich (St. Louis, MO). Acetylcholine 
(ACh) chloride, atropine (generalized muscarinic antagonist), mecamylamine 
hydrochloride (MCA, generalized nAChR antagonist), α-conotoxin MII (α-CT, α3β2- and 
β3-nAChR antagonist), methyllycaconitine citrate (MLA, α7-nAChR antagonist), and (±)-
vesamicol hydrochloride (VAChT antagonist) were purchased from Tocris (Ellisville, 
MO). Human IGF-II was obtained from Millipore, Temecula, CA. 
VAChT, AChE polyclonal antibodies and human sigma receptor monoclonal antibody 
were obtained from Santa Cruz Biotechnology, Santa Cruz, CA. CHT1 polyclonal and ChAT 
monoclonal antibodies were obtained from Millipore Inc. Phospho-Akt (Thr308), Phospho Akt 
(Ser473) and total Akt polyclonal antibodies were obtained from Cell Signaling Inc (Danvers, 
MA).  HA monoclonal antibody was purchased from Covance (Princeton, NJ).  The secondary 
donkey-anti-rabbit, rabbit-anti-mouse antibodies were obtained from Thermo Scientific, 
Rockford, IL. 
The plasmid pcDNA3-HA-Akt-CA (T308D, S473D) (Addgene plasmid 142571) 
was a kind gift from Dr. Jim Woodgett, University of Ontario. 
 
Cell lines and Cell Culture  
The human squamous cell carcinoma of the lung (SCC-L) cell line NCI-H520 (hereafter 
referred to as H520) was obtained from American Type Culture Collection (Rockville, MD). 
H520 cells were grown in RPMI-1640 medium (Mediatech, Inc, Manassas, VA) supplemented 
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with 2 mM glutamine, 100 U/mL penicillin, 50 μg/mL streptomycin, and 10% FBS.  The cells 
were incubated at 37°C in 5% CO2. The H520 cells were authenticated by the ATCC Cell 
Authentication service in October 2012. They used Short Tandem Repeat (STR) profiling, for 
authentication of these cells and the results are summarized in Supplementary Figure 1. 
Primary human pulmonary alveolar epithelial cells (HPAEpiCs) were obtained from 
ScienCell (Carlsbad, CA) and cultured in alveolar epithelial cell medium (AEpiCM) 
supplemented with 5% FBS.  All experiments with the HPAEpiCs were performed between 
passage numbers 3-7.  HPAEpiCs were characterized by ScienCell Inc. by immunostaining for 
specific markers.  A certificate of analysis was provided. 
 
Lysates and Western Blotting 
Lysates for each cell line were made using the NP-40-based lysis protocol (1, 2). Cells 
were harvested and washed three times with ice cold 1X PBS. Cells were then lysed with M2 
lysis buffer (20 mM Tris, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 4 µM 
DTT, 5 mM PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 25 µg/ml leupeptin, 5 
µg/ml pepstatin, 5 µg/ml aprotinin, 25 µg/ml trypsin-chymotrypsin inhibitor). Seventy five 
microliters of lysis buffer was added for every 20 µL of packed cell volume. The lysate was 
rotated at 4oC for 30 minutes and subsequently spun at 15000g for 15 minutes at 4oC. The 
supernatant was collected for further analysis. The protein concentration of the lysate was 
measured using a Bradford Reagent (Bio-Rad Labs, Hercules, CA, USA). Two hundred 
microgram aliquot of the protein was run on a 10% SDS-PAGE gel and transferred onto 
nitrocellulose membranes (Bio-Rad Labs).  
The relative expression of the indicated proteins was analyzed by western blotting. The 
signal obtained in the western blot experiments was detected by the SuperSignal West Dura 
Extended Duration Substrate (Pierce Biotechnologies, Rockford, IL, USA). The results of the 
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western blotting assays were quantitated by ImageJ 1.46p (National Institutes of Health, 
Bethesda, MD, USA). 
 
BrdU Proliferation Assays  
BrdU assays were used to examine the proliferative effects of ACh on A549 or H358 
cells (3, 4). A549 cells were plated in 8-well chamber slide at a density of 10,000 cells/well in 
SF-RPMI. After overnight incubation, the medium was aspirated and replaced with SF-RPMI 
containing ¼ growth factors (referred to hereinafter as SF-RPMI-R) for 24-hours. After 24-hours, 
these cells were treated with varying concentrations of ACh, and incubated for 48-hours at 
37°C. The rate of BrdU incorporation in cells was measured by the BrdU Labeling and Detection 
Kit II (Roche Applied Science, Indianapolis, IN, USA) according to manufacturer’s instructions. 
The magnitude of BrdU incorporation in control cells was considered to be equal to 1, and the 
BrdU incorporation observed in ACh-treated cells was calculated as fold-increase relative to the 
control cells. The assay was completed in duplicate, and the whole experiment was performed 
two independent times.  
BrdU assays were also performed to examine the effect on vesamicol on EGF-induced 
proliferation as well as IGFII-induced proliferation in human BAC cells. A549 cells were seeded 
in 8-well chamber slides as described above. Subsequently the cells were rendered quiescent in 
serum-free RPMI for 24-hours. After 24-hours, cells were treated with 10ng/ml EGF (or 20ng/ml 
IGF-II) in the presence or absence of 50 µM vesamicol for 36-hours at 37°C. The concentrations 
of EGF and IGF-II were selected from previous publications.  The BrdU assay was performed as 
described above.  
 
MTT Assay  
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A549 or H358 cells were plated in 96-well plates at a density of 2500 cells/well in SF-
RPMI. After overnight incubation at 37oC, the medium was replaced with SF-RPMI-R. Cells 
were treated with 100 nM nicotine in the presence or absence of varying concentrations of 
vesamicol for 48-hours. After 48-hours, the MTT assay was performed as described previously 
(1, 4). The experiment was performed two independent times with three replicates in each 
experiment for each cell line. 
 
siRNA Transfection Assays  
Chemically synthesized, double stranded VAChT-siRNA and Sigma receptor-siRNA 
(sigmaR-siRNA) were purchased from Santa Cruz Biotechnologies, Inc. The transfection 
experiments were performed in A549 and H358 cells. The transfection of 75 nM VAChT-siRNA 
or control-siRNA was performed by using Oligofectamine reagent (Invitrogen, Carlsbad, CA, 
USA), according to the manufacturer’s protocol (1, 2). Eighteen hours post-transfection, the 
cells were incubated in SF-RPMI-R media for 24 hours, after they were treated with 100 nM 
nicotine in the presence or absence of 50 µM vesamicol for 48 hours. The effect of VAChT-
siRNA or Sigma-R-siRNA on the apoptotic activity of vesamicol was measured by the caspase-
3 activity kit (Millipore). A non-targeting siRNA sequence (Santa Cruz Biotechnologies, Inc.) was 
used as a control for the transfection experiments (5, 6) (1). The entire experiment was 
repeated with a second VAChT-siRNA (Ambion, Grand Island, NY, USA). Each transfection was 
performed in duplicate, and the entire assay was performed 2 independent times. 
 The efficiency of VAChT-siRNA transfection was assessed by the VAChT ELISA kit 
(Antibodies Online) in A549 and H358 cells. Western blotting experiments were performed to 
examine the expression of the Sigma-receptor after siRNA transfection (1). The results of the 
western blotting assays were quantitated by ImageJ 1.46p (National Institutes of Health, 
Bethesda, MD, USA). 
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Transient Transfection Assays  
A549 or H358 cells were cultured to 50-70% confluence in SF-RPMI medium and 
transfected with 4 µg of pcDNA3-Akt-constitutively active (pcDNA3-HA-Akt-CA) using Fugene 
HD transfection reagent (Roche Applied Sciences, Indianapolis, IN), according to the 
manufacturer’s protocols (2, 5). Cells transfected with the empty vector pcDNA3 were used as a 
control (mock transfected). After overnight incubation, the cells were rendered quiescent by 
incubating them in SF-RPMI-R medium for 24 hours. Subsequently, the cells were treated with 
100 nM nicotine in the presence or absence of 50 M vesamicol for 48 hours at 37°C. Lysates 
were made and the apoptotic activity of vesamicol was measured by the caspase-3 activity kit 
(EMD Millipore Corporation). The experiment was performed two independent times with two 
replicates in each experiment. The over-expression of the plasmid after transfection was 
analyzed by western blotting. The results of the western blotting assays were quantitated by 
ImageJ 1.46p (National Institutes of Health, Bethesda, MD, USA). 
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Figure S1. A summary of the cell line authentication data for A549, H520 and H358 cells was 
obtained from the ATCC Cell Line Authentication service. They used Short Tandem Repeat 
(STR) profiling, for authentication of these cells. As indicated in the last row, the profile of the 
cell lines used in this study were a 100% match for A549, NCI-H520 and NCI-H358  profile 
described in the ATCC database. 
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Figure S2. Full screen western blots (corresponding to Figure 1B) for the cholinergic proteins 
namely ChAT, VAChT, AChE and CHT1 in normal human pulmonary alveolar epithelial cells 
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(HPAEpiCs) and human BAC cell lines. The human SCC-L cell line H520 was used as the 
positive control for the immunoblotting experiments. 
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Figure S3. Normal lung tissues contain ChAT and VAChT.  Immunohistochemical staining of 
normal lung TMA reveals the presence of ChAT and VAChT on normal lung tissues isolated 
from patients.  The normal lung tissue microarray (TMA) was stained with ChAT monoclonal 
antibody and VAChT polyclonal antibody, used in the western blotting experiments outlined in 
Figure S2.  The slides were counterstained with hemotoxylin.  The staining of both ChAT and 
VAChT was observed to be cytoplasmic, adjacent to the hemotoxylin-stained dark nuclei in the 
tissue sample. This TMA contained 20 normal lung tissue samples. Photographs of four 
representative samples are shown above. Scale bar = 20µm 
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Figure S4. Nicotine-induced ACh production is mediated by 7-, 3β2- and β3-containing-
nAChR subunits and requires VAChT and CHT1. A.  Nicotine-induced ACh production was 
inhibited by 1 µM of the generalized nAChR antagonist, mecamylamine (MCA), but was 
unaffected by 1 µM of the muscarinic receptor antagonist atropine in A549 and H358 cells. The 
treatment of A549 and H358 human BACs with MCA or atropine alone had little to no effect on 
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ACh levels. B. The treatment of A549 and H358 human BAC cells with 1 μM of 
methyllylcaconitine (MLA), -bungarotoxin (-BT) and -conotoxin (α-CT) MII ablated nicotine-
induced ACh production, whereas DHβE (3β2 and 4β2 nAChR antagonist) had little to no 
effect. C. Vesamicol and hemicholinium ablated nicotine-induced ACh production in A549 and 
H358 human BACs. Each sample was analyzed in triplicate. Data represent mean + SEM from 
two independent experiments. Results indicated by a different letter are significantly different (P 
< 0.05). 
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Figure S5. VAChT and ChAT are expressed on human BACs. ELISA assays were used to 
measure the relative levels of ChAT and VAChT on A549, H358, H650 human BAC cells and 
HPAEpiC normal lung cells.  H520 human SCC-L cells were used as the positive control for the 
assay.  The absorbance obtained in H520 lysates was taken as 1 and the absorbance values in 
the other cell lines were calculated as fold changes over H520.  Each sample was assayed in 
duplicate and the entire experiment was repeated twice.  Data represent mean + SEM from two 
independent experiments. Results indicated by a different letter are significantly different (P < 
0.05). 
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Figure S6.  The transfection of VAChT-siRNA and sigma-R-siRNA suppresses the expression 
of these proteins in human BACs. ELISA assays show that transfection of VAChT-siRNA-1 and 
VAChT-siRNA-2 decrease the expression of VAChT in A549 cells A. and H358 cells B.  Each 
sample was assayed in duplicate and the entire experiment was repeated twice.  Data represent 
mean + SEM from two independent experiments. Results indicated by a different letter are 
significantly different (P < 0.05).Western blotting experiments demonstrate that the level of 
sigma-receptor is decreased after siRNA transfection in A549 cells C. and H358 cells D. The 
western blot was quantitated using NIH ImageJ 1.46p.
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Figure S7.  A. The pro-apoptotic activity of 10µM vesamicol in nicotine-treated A549 cells was 
abrogated by two independent VAChT-siRNA , namely VAChT-siRNA-1 and VAChT -siRNA-2. 
The transfection of a non-targeting control-siRNA had no effect on vesamicol-induced apoptosis 
in A549 cells.  Both the VAChT-siRNA had no effect on only nicotine-treated A549 cells (white 
bars).  B. The experiment was repeated in H358 human BAC cells and similar results were 
obtained.  C.  The apoptotic effects of 25µM vesamicol in nicotine-treated A549 cells was 
reversed by VAChT-siRNAs , namely VAChT-siRNA-1 and VAChT -siRNA-2.  The VAChT-
siRNAs did not have any effect on nicotine-treated A549 cells (white bars). D.  The experiment 
was also performed in H358 cells and similar results were obtained.  E. ELISA assays show that 
the transfection of both the VAChT-siRNAs caused robust suppression of VAChT levels on 
A549 and H358 cells. Data represent mean + SEM from two independent experiments. Results 
indicated by a different letter are significantly different (P < 0.05). 
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Figure S8.  Western blot analysis shows that pcDNA3-HA-Akt-CA is overexpressed upon 
transfection in A549 cells A. and H358 cells B. The transfection was performed in duplicate and 
the whole experiment was repeated twice. The western blot was quantitated using NIH ImageJ 
1.46p. 
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